S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Phreesia (PHR) Stock Price, News & Analysis

$23.95
-0.44 (-1.80%)
(As of 03/28/2024 ET)
Today's Range
$23.73
$24.98
50-Day Range
$22.70
$28.87
52-Week Range
$12.05
$34.98
Volume
666,646 shs
Average Volume
576,215 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.62

Phreesia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
32.0% Upside
$31.62 Price Target
Short Interest
Bearish
3.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.49mentions of Phreesia in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$936,390 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

85th out of 938 stocks

Business Services, Not Elsewhere Classified Industry

13th out of 89 stocks

PHR stock logo

About Phreesia Stock (NYSE:PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

PHR Stock Price History

PHR Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Phreesia (NYSE:PHR) Rating Reiterated by Stephens
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Phreesia gets new technology chief
Phreesia (NYSE:PHR) Stock Rating Reaffirmed by Raymond James
Phreesia's (PHR) Neutral Rating Reiterated at DA Davidson
Stock Market News for Mar 18, 2024
PHR Dec 2024 20.000 put
PHR Jun 2024 17.500 call
See More Headlines
Receive PHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/29/2024
Next Earnings (Estimated)
5/29/2024
Fiscal Year End
1/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Employees
1,438
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.21
High Stock Price Target
$40.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+34.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-136,880,000.00
Pretax Margin
-37.99%

Debt

Sales & Book Value

Annual Sales
$356.30 million
Book Value
$4.46 per share

Miscellaneous

Free Float
53,117,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.93
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

PHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Phreesia stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHR shares.
View PHR analyst ratings
or view top-rated stocks.

What is Phreesia's stock price target for 2024?

14 Wall Street analysts have issued 12-month price objectives for Phreesia's stock. Their PHR share price targets range from $23.00 to $40.00. On average, they predict the company's share price to reach $31.62 in the next year. This suggests a possible upside of 32.0% from the stock's current price.
View analysts price targets for PHR
or view top-rated stocks among Wall Street analysts.

How have PHR shares performed in 2024?

Phreesia's stock was trading at $23.15 at the start of the year. Since then, PHR shares have increased by 3.5% and is now trading at $23.95.
View the best growth stocks for 2024 here
.

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024.
View our PHR earnings forecast
.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. The business had revenue of $95 million for the quarter, compared to analyst estimates of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative trailing twelve-month return on equity of 53.33%. The business's revenue was up 24.0% on a year-over-year basis. During the same period last year, the company earned ($0.72) earnings per share.

What ETFs hold Phreesia's stock?
What guidance has Phreesia issued on next quarter's earnings?

Phreesia updated its FY 2025 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $424.0 million-$434.0 million, compared to the consensus revenue estimate of $428.1 million.

What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).

When did Phreesia IPO?

Phreesia (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray acted as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.32%), Vanguard Group Inc. (8.32%), Brown Advisory Inc. (7.10%), Franklin Resources Inc. (2.67%), GW&K Investment Management LLC (2.17%) and Ophir Asset Management Pty Ltd (1.98%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, David Linetsky, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub and Randy Rasmussen.
View institutional ownership trends
.

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PHR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners